33.98
+0.12%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About EyeGate Pharmaceuticals
Its shares trade under the ticker EYEG. It has been listed since 13 February 2015. In the fiscal year to 31 December 2020, it reported revenue of $10,000 and a net loss of $8.1m. At that date it held total assets of $15.2m and shareholders' equity of $7.0m.
EyeGate Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. The company is headquartered in Waltham, Massachusetts. The company went IPO on 2015-02-13. The firm is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The firm's lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System. The firm is developing EGP-437 for the treatment of various inflammatory conditions of the eye, including uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris and/or ciliary body, and macular edema, an abnormal thickening of the macula associated with the accumulation of excess fluids in the extracellular space of the neurosensory retina. The EyeGate II Delivery System is designed to deliver optimal quantities of drugs to the anterior or posterior segments of the eye.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 13 Feb 2015
- Employees
- 10
- Website
- eyegatepharma.com ↗
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- EyeGate Pharmaceuticals Inc holds several strengths that contribute to its competitive advantage. One noteworthy strength is its innovative product portfolio, which includes cutting-edge ophthalmic drug delivery technologies. These technologies provide improved treatment options for various eye conditions, giving the company an edge over competitors. Additionally, EyeGate Pharmaceuticals has a strong team of experienced professionals who bring industry expertise and knowledge to drive the company's growth.
Weaknesses
- Despite its strengths, EyeGate Pharmaceuticals Inc also faces certain weaknesses that may hinder its progress. One weakness is the company's heavy reliance on a limited number of products. This narrow product range exposes EyeGate Pharmaceuticals to potential market risks, as any setbacks or failures in these key products could significantly impact the company's financial stability. Furthermore, the company's current geographical reach may be limited, making it vulnerable to local market fluctuations.
Opportunities
- EyeGate Pharmaceuticals Inc can explore several opportunities to grow and expand its market presence. With increasing consumer demand for advanced ophthalmic treatments, the company has the potential to tap into emerging markets and expand its product offerings. By leveraging its innovative drug delivery technologies, EyeGate Pharmaceuticals can also explore partnerships or collaborations with pharmaceutical giants seeking to enhance their ophthalmic product portfolios. Furthermore, the company may explore untapped markets, both domestically and internationally, to broaden its customer base.
Threats
- As with any business, EyeGate Pharmaceuticals Inc faces potential threats that could impact its operations and growth prospects. One notable threat is the presence of intense competition within the pharmaceutical industry. The market is saturated with established players who possess significant resources, making it challenging for EyeGate Pharmaceuticals to compete effectively. Additionally, regulatory compliance and approval processes pose a threat, as any delays or rejections may hamper product launches and profitability. Lastly, economic uncertainties and fluctuations in healthcare policies could affect the company's revenue and market opportunities.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.